Recruiting
Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.
This is multicentric, spontaneous, observational, retrospective and prospective study.
ClinicalTrials.gov IDNCT05817227
PhaseNot Applicable
Enrollment300
SponsorNational Cancer Institute, Naples
Age18 Years and older
SexFEMALE
Conditions studied
Breast Cancer
About this study
This is multicentric, spontaneous, observational, retrospective and prospective study.
Primary outcomes
- Use of immunohistochemistry investigation (IHC) (3 years)
- Prospective evaluation of expression of some selenoproteins by kit ELISA in plasma samples (3 years)
Eligibility information
Inclusion Criteria:
* TNBC breast cancer patients, before any drug treatment
* healthy women aged 25-60
Exclusion Criteria:
* donors suffering from diabetes, hypertension, active infectious states, HIV infection, Hepatitis B or C, chronic inflammatory diseases, current or previous neoplasms, heart disease or drug treatment.
Study locations
- Istituto Nazionale Tumori - Fondazione "G.Pascale", IRCCS, Naples, Napoli 80131 Italy
- Istituto Nazionale Tumori Regina Elena, Roma, Roma 00144 Italy
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-19.